Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 3,001–3,100 of 4,108
Nutritional Management of Osteoporosis: It’s More Than Calcium
Singh, P., Paul, V., & Pundir, A. K. S. (2021) · International Journal of Current Research and Review · doi:10.31782/ijcrr.2021.131401 · Cited by 2
In reply—Adverse Cardiac Effects of Bisphosphonates
Pittman, C. B. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.04.014 · Cited by 2
Cost‐Effectiveness of Osteoporosis Treatment
Tosteson, A. N. A. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch55 · Cited by 2
Li, Y., Wang, X., Zhang, R., Zhu, S., Wang, L., Huang, J., Gan, X., Xie, S., Wu, T., & He, C. (2021) · medRxiv · doi:10.1101/2021.07.12.21260370 · Cited by 3
FRAX ® : Assessment of Fracture Risk
Kanis, J. А. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch34 · Cited by 2
Levy, B. T., Hartz, A., & Xu, Y. (2010) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2010.01.090216 · Cited by 2
Androgen-Deprivation Bone Loss in Patients With Prostate Cancer
Abarado, C., & Mahon, S. M. (2010) · Clinical journal of oncology nursing · doi:10.1188/10.cjon.191-198 · Cited by 1
Medications for osteoporotic pain
Shin, S. W. (2017) · The Korean journal of pain · doi:10.3344/kjp.2017.30.2.85 · Cited by 1
Age-Related Physiological Changes: An Overview
Sames, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-60912-8.00003-8 · Cited by 6
Introduction: Causes and Risk Factors for Male Osteoporosis
Infante, M., Caprio, M., & Fabbri, A. (2020) · Trends in andrology and sexual medicine · doi:10.1007/978-3-319-96376-1_5 · Cited by 1
Postoperative Bone Mineral Health Optimization in the Geriatric Patient
Kondapalli, A. V., & Walker, M. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-78969-5_11 · Cited by 1
Osteoporosis Update for Primary Care Physicians
Miedany, Y. M. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-87950-1_16 · Cited by 2
Miedany, Y. M. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-87950-1_13 · Cited by 1
Randolph, S. A. (2016) · Workplace Health & Safety · doi:10.1177/2165079916674484 · Cited by 1
Paccou, J., Genser, L., Lespessailles, É., Bertin, É., Javier, R., Duclos, M., Joly, A.-S., Boirie, Y., Pattou, F. N., Delarue, J., et al. (2022) · Revue du Rhumatisme · doi:10.1016/j.rhum.2022.10.005 · Cited by 1
Study of pelvic organ prolapse as a predictor of osteoporotic fracture risk
Rísquez, A. C. F., Mendoza, N., García, A. C., Elósegui, J. J. H., & Lorite, J. P. (2022) · Gynecological Endocrinology · doi:10.1080/09513590.2022.2159024 · Cited by 1
The Relationship of Osteoporosis with Menopause: Review of Article
Alsarraje, H. A., & Alhyali, L. K. (2022) · International Journal of Research in Medical Sciences & Technology · doi:10.37648/ijrmst.v14i01.016 · Cited by 3
Launching the Emirates Osteoporosis Society (EOS) Guidelines 2022 in the United Arab Emirates
Izzi, M. A., Suhaili, A. A., El-Serafi, A. T., Abogamal, A. F., Tapponi, L., & Brodzinski, Z. (2023) · New Emirates Medical Journal · doi:10.2174/04666230126094059 · Cited by 2
Design of a Computer Model for the Identification of Adolescent Swimmers at Risk of Low BMD
Marín-Puyalto, J., Gómez‐Cabello, A., Gómez‐Bruton, A., Matute-Llorente, Á., Castillo-Bernad, S., Lozano‐Berges, G., González‐Agüero, A., Casajús, J. A., & Vicente‐Rodríguez, G. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20043454 · Cited by 2
“Public health recommendations include an osteoporosis screening for the elderly [17] using the current gold standard method for BMD evaluation, which is dual-energy X-ray absorptiometry (DXA).”
MethodHigh and extremely high risk of osteoporotic fractures in Chilean women
Gavilánez, E. L., Naula, L. I., Chávez, M. N., et al. (2023) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.20960/revosteoporosmetabminer.00001 · Cited by 1
Kim, M., & Choi, M. (2023) · 대한지역사회영양학회지 · doi:10.5720/kjcn.2023.28.4.282 · Cited by 1
Minimally Invasive Treatment of Skeletal-Related Events
Gautam, A. T., & Hertel, F. (2023) · Springer eBooks · doi:10.1007/978-3-030-93702-7_19-1 · Cited by 1
Greenfield, P. T., Coble, T. J., Bell, J. A., et al. (2024) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2024.02.005 · Cited by 1
Bakılan, F., Sarıçimen, G., Ortanca, B., et al. (2024) · Turkish Journal of Osteoporosis · doi:10.4274/tod.galenos.2023.23500 · Cited by 1
“The American National IOF recommends that DXA be requested for all adults over 50 years of age with fractures (21).”
BackgroundFall Prevention Intervention Model in Primary Care: STRIDE
McMahon, S., & Latham, N. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-56204-4_22 · Cited by 1
Chen, S., Guo, L., Zhao, H., Wan, X., & Zang, J. (2024) · Medicine · doi:10.1097/md.0000000000038559 · Cited by 3
“[3] With the aging population in our country continually expanding, the societal challenges presented by OP and its complications will become more severe.”
BackgroundZhang, L., Hu, F., Li, K., Cao, L., Zhang, J., Xie, T., & Zhao, M. (2024) · American Journal of Translational Research · doi:10.62347/echr4598 · Cited by 1
Manejo rehabilitador y ortopédico de las fracturas por compresión vertebral osteoporótica
Taborda, A. T., Benadiva, C. D. M., & Tarifa, P. S. (2024) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recot.2024.10.003 · Cited by 3
Tombak, Y., Umay, E., Nazlı, F., et al. (2024) · Journal of Clinical Medicine of Kazakhstan · doi:10.23950/jcmk/15703 · Cited by 1
Lee, S., Park, S., & Kim, T. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121623 · Cited by 1
“Osteoporosis is a metabolic disease characterized by bone mass reduction and bone structure deterioration [1,2].”
Phannarus, H., Chansaengpetch, S., Virojskulchai, T., et al. (2025) · Siriraj Medical Journal/San Sirirat · doi:10.33192/smj.v77i1.271734 · Cited by 1
“25 6) Sarcopenia screening: The modified version of the Mini-Sarcopenia Risk Assessment (MSRA-5) 26 , a five-question screening tool, was employed to assess the risk of sarcopenia.”
Sridhar, D. C., Ahuja, S. P., Sidonio, R. F., Chitlur, M., Sharathkumar, A. A., Tobase, P., Acharya, S. S., Isaac, D., Kulkarni, R., & Johnson, M. M. (2025) · Haemophilia · doi:10.1111/hae.70027 · Cited by 1
Ayturk, S. A., Taşkıran, Ö. Ö., Tohma, E. K., et al. (2025) · Journal of Bone Metabolism · doi:10.11005/jbm.24.787 · Cited by 1
“[14 ] Drug response was assessed based on the change in BMD, at baseline and after 12 months of treatment with BP. Drug response was classified as “inadequate” if there is both an incident fracture and a > 2% decrease in BMD, “possibly inadequate” if there is either an incident fracture or a > 2%…”
Kadri, A., Liu, D., Sorensen, A., Binkley, N., Ross, A. B., & Anderson, P. A. (2025) · Journal of Neurosurgery Spine · doi:10.3171/2025.1.spine24976 · Cited by 3
Ma, X., Ma, Y., Ma, X., Zhang, Z., & Li, Y. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70402 · Cited by 3
Kulkarni, R. S., Kulkarni, R. A., Kulkarni, R. R., et al. (2025) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-025-04339-9 · Cited by 1
“Targeted treatment of high-risk populations can substantially reduce hip fracture incidence [7].”
Ardelean, A., Ţiţ, D. M., Furau, R., Todut, O. C., Bungau, G. S., Pavel, R. M. S., Uivaraseanu, B., Bei, D., & Furau, C. G. (2025) · Diagnostics · doi:10.3390/diagnostics15151972 · Cited by 6
“Understanding the real-world patterns of skeletal fragility indicators and treatment uptake is critical for improving secondary prevention and optimizing long-term outcomes [11,12].”
Chahal, K., Nguyen, J., Rajesh, D. A., et al. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.70060 · Cited by 1
“Guidelines urge clinicians to initiate treatment for osteoporosis in persons with hip fractures regardless of bone mineral density testing [3, 4].”
A phase-of-care approach to improve geriatric fracture care
Nguyen, A. T., Lee, P., Rodriguez, E. K., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00974-3 · Cited by 1
Arana, A., Ocerin, I., Lopez, J. I., Echevarría, E., & Larrinaga, G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207398 · Cited by 1
“Secondary osteoporosis, on the other hand, is associated with medication use, lifestyle habits, or medical conditions [5,6] that have a deleterious effect on bone.”
Optimizing Women’s Health Over the Lifespan: Why Body Composition, Bone Health and Fitness Matter
Bovard, R., Nadeau, A. M., Starchook-Moore, M. N., Dabrowski, D. S., Grob, C. H., & Anderson, P. J. (2025) · American Journal of Lifestyle Medicine · doi:10.1177/15598276251390867 · Cited by 2
Research Status and Hot Spot Visualization Analysis of Osteoporosis from 2014 to 2025
Huang, Y., Wang, F., Lian, K., Li, L., & Wang, Z. (2025) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s541592 · Cited by 2
Bhalerao, P., Magre, M., Mandlik, S. K., Shinde, V. M., & Mandlik, D. S. (2025) · Digital Chinese Medicine · doi:10.1016/j.dcmed.2025.09.013 · Cited by 2
IL-34 as a Novel Mediator Linking Vitamin D Deficiency with Osteoporosis and Knee Osteoarthritis
Tarabeih, N., Sleiman, A., Kalinkovich, A., Ashkenazi, S., Shalata, A., & Livshits, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211090 · Cited by 2
“OP was diagnosed using dual-energy X-ray absorptiometry (DXA); following World Health Organization (WHO) criteria, a T-score of ≤− 2.5 at either the lumbar spine or femoral neck was considered diagnostic [107].”
InfluentialZhang, Q., Zhang, X., Zhang, S., lv, G., Wang, Y., Shi, X., Li, Y., Ding, L., & Dong, L. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02788-z · Cited by 2
Qian, Y., Chen, H., Wang, J., Ma, C., & Huang, W. (2025) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_63_25 · Cited by 1
“[3,4]”
Chen, L., Huang, H., & Gao, Z. (2025) · Apmis · doi:10.1111/apm.70099 · Cited by 1
“However, approximately 30% of vertebral fractures occur without acute pain [5], and many OPF cases present asymptomatically, making it challenging to differentiate OP from OPF during early-stage prevention and diagnosis [6].”
Usategui‐Martín, R., Mateo, J., Campillo-Sánchez, F., Torres, A. M., de Temiño, Á. R., Gil, J., Martín-Millán, M., Hernández, J. L., & Pérez-Castrillón, J.-L. (2025) · Scientific Reports · doi:10.1038/s41598-025-27226-z · Cited by 3
Alghamdi, F., Obotiba, A. D., Meertens, R. M., Alshalawi, O., Mokbel, K., Strain, W. D., & KNAPP, K. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238558 · Cited by 1
“The measurements were based on the WHO osteoporosis T-score classification and the NICE guidelines for fragility fracture risk assessment, observing healing responses, and having a reliable reference range [36–38].”
Tao, Y., Yao, C., Liu, R., Qiu, H., Liu, X., Wang, B., & Li, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1737713 · Cited by 3
“…atrial fi brillation (15), ventricular arrhythmias (16), hypertension (17),, coronary heart disease (18), diabetes (19), stroke (20), pneumonia (21), chronic kidney disease (22), liver disease (23), rheumatoid arthritis (24), asthma (25), thyroid dysfunction (26), osteoporosis (27), and anemia (28).”
Tweekittikul, A., Srinonprasert, V., & Sura-amonrattana, U. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06689-9 · Cited by 2
Individualized Fracture Prevention for Postmenopausal Women with Osteopenia
Mun, J., Kim, M. K., Song, J., Chung, Y., Park, J., & Park, J. (2025) · Journal of Menopausal Medicine · doi:10.6118/jmm.25148 · Cited by 2
“…at the femoral neck, total hip, or lumbar spine as identified by dual-energy X-ray absorptiometry (DXA) if their 10-year probability of hip fracture is ≥ 3% or if their 10-year probability of a major osteoporosis-related fracture is ≥ 20%, according to the US-adapted WHO FRAX ® model [13,14].”
Pinto, N., Machado, A., Matos, A., Cardoso, C. S., Figueiredo, J. M., Silveira, J. C., Silva, J. D. O. E., Gonçalves, D., Valente, P., Lourenço, M. H., et al. (2026) · Cureus · doi:10.7759/cureus.100582 · Cited by 1
Shetty, S., Jose, J., Gopan, G., et al. (2026) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-02039-9 · Cited by 1
Cao, D., Li, X., Gu, W., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-40167-5 · Cited by 1
Mühlenfeld, N., Busch, H.-J., Stephan, D., et al. (2026) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-026-06230-6 · Cited by 1
“OP is characterized by a decrease in bone mass and deteriorated bone tissue and architecture, all of which raise the risk of fracture [13].”
Ye, Q., Tao, Q., Long, X., Lou, F., Li, J., Li, X., Tan, D., & Xiao, J. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-04935-4 · Cited by 3
Frediani, B., Gaudio, A., Giannini, S., et al. (2026) · Archives of Osteoporosis · doi:10.1007/s11657-026-01678-w · Cited by 1
“This condition primarily affects older adults, particularly postmenopausal women, due to hormonal changes that accelerate bone loss [4].”
Liu, A., Liu, J., & Wu, Q. F. (2026) · Calcified Tissue International · doi:10.1007/s00223-026-01497-8 · Cited by 2
“Addressing these priorities will advance precision-based fracture risk assessment, enabling targeted and personalized prevention strategies for osteoporosis management. and polygenicity [9–13].”
Vanitcharoenkul, E., Adulkasem, N., Unnanuntana, A., et al. (2026) · BMC Public Health · doi:10.1186/s12889-026-27158-x · Cited by 1
“Osteoporosis and sarcopenia prevalence were evaluated using dual-energy X-ray absorptiometry according to World Health Organization criteria [14].”
Testosterone and Bone Health in Men
Kafel, H., & Basaria, S. S. (2026) · Current Osteoporosis Reports · doi:10.1007/s11914-026-00971-4 · Cited by 2
“In addition to pharmacologic intervention, conventional measures such as sufficient calcium and vitamin D intake, regular weight-bearing exercises, and the avoidance of smoking and excessive alcohol consump - tion should be encouraged [67–69].”
Zhang, Y.-W., Wei, P., Feng, L.-S., Dong, Z.-L., Hu, Y., Zhang, H., Fan, Z.-H., Wang, P., Wang, G.-C., Ma, Y.-H., et al. (2026) · Bone · doi:10.1016/j.bone.2026.117985 · Cited by 1
Obesity and bone health: reconciling the density–fragility paradox
Sulimani, R. A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1864169 · Cited by 4
Romosozumab in postmenopausal women with classical Osteogenesis imperfecta
Bartosik, M., Windels, O., von Brackel, F. N., Amling, M., & Oheim, R. (2026) · Archives of Osteoporosis · doi:10.1007/s11657-026-01744-3 · Cited by 2
“Severe osteoporosis was defined as a lowest T-score ≤ −2.5 by DXA with at least one vertebral fragility fracture [17].”
InfluentialTHE EFFECT OF VARIOUS PATHOLOGIES ON BONE QUALITY
Porter, D. S. (2014) · UKnowledge (University of Kentucky) · Cited by 1
Loh, F. E., Stuart, B., & Zuckerman, I. H. (2015) · Journal of Pharmaceutical Health Services Research · doi:10.1111/jphs.12082 · Cited by 1
Aromatase Inhibitors and Osteoporosis - Risk, Prevention and Treatment Review
Tanaka, W. R. T., & Razaq, M. (2015) · Journal of Osteoporosis and Physical Activity · doi:10.4172/2329-9509.1000155 · Cited by 1
Solomon, D. H., Brown, E. M., Chandler, D., Bower, A. G., Barron, R. L., Mogun, H., & Franklin, J. M. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2757-7 · Cited by 1
Sensitivity of osteoporosis screening guidelines for eventual hip fracture in older male veterans
Pavon, J. M., Sanders, L. L., Sloane, R. J., & Colon-Emeric, C. S. (2014) · BoneKEy Reports · doi:10.1038/bonekey.2014.25 · Cited by 1
Riesgo de fractura según la herramienta FRAX en un centro de atención primaria
Monje, F. M., Pérez, Y., Gálvez, J. M. C., et al. (2013) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2013.05.006 · Cited by 1
Primary Prevention of Osteoporosis: Time to Redefine the Wheel?
Babatunde, O. O. (2014) · Journal of Osteoporosis and Physical Activity · doi:10.4172/2329-9509.1000e107 · Cited by 2
Lafleur, J., Sl, D., Curtis, et al. (2013) · Cited by 1
Utility of Vertebral Fracture Recognition in Osteoporosis
Vokes, T. (2016) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-015-9202-0 · Cited by 1
Hoffman, V., Xue, F., Gardstein, B. M., Skerry, K., Critchlow, C. W., & Enger, C. L. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3402-9 · Cited by 1
Osteoclast-Mediated Pain in Osteoporosis
Iba, K., & Yamashita, T. (2015) · Springer eBooks · doi:10.1007/978-4-431-55778-4_2 · Cited by 1
Banakh, I. (2016) · International Journal of Orthopaedics · doi:10.17554/j.issn.2311-5106.2016.03.158 · Cited by 1
Gifre, L., Monegal, A., Filella, X., et al. (2015) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2015000400002 · Cited by 1
Osteoporosis and other metabolic bone disorders
Bellantoni, M. F. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107294967.032 · Cited by 1
Minimizing cancer’s impact on bone with denosumab: current and future perspectives
Gradishar, W. J., Gralow, J. R., Jones, S. E., & Collins, H. (2013) · Community Oncology · doi:10.12788/j.cmonc.0024 · Cited by 1
Fu, S., & Sheng, Z. (2017) · Osteoporosis International · doi:10.1007/s00198-016-3867-1 · Cited by 1
Management of Osteoporosis in Postmenopausal Breast Cancer Survivors
Jiang, X., Schnatz, P. F., & Kagan, R. (2017) · Springer eBooks · doi:10.1007/978-3-319-42451-4_18 · Cited by 1
Skeletal Fragility, a Common Menopausal Burden: Risk Assessment, Diagnosis, and Management
Holick, M. F. (2017) · Springer eBooks · doi:10.1007/978-3-319-42451-4_8 · Cited by 1
Peripheral Artery Disease and Osteoporosis
Basgoz, B., Aykan, M., & Tasci, I. (2017) · International Journal of Vascular Surgery and Medicine · doi:10.17352/2455-5452.000020 · Cited by 1
The Bisphosphonates versus Denosumab Efficiency in Postmenopausal Osteoporosis Treatment
Ciumărnean, L., Milaciu, M. V., Alb, M. G., Moldovan, R. T., & Sâmpelean, D. P. (2017) · Balneo Research Journal · doi:10.12680/balneo.2017.139 · Cited by 1
Osteoporosis in Rheumatologic Conditions and Inflammatory Disorders
Oleson, C. V. (2017) · Springer eBooks · doi:10.1007/978-3-319-45084-1_12 · Cited by 1
Prediction of the Risk of Osteoporotic Fractures Using Bayesian Belief Networks
Dmitriev, G. A., Vetrov, A. N., & Al-Fakih, A. S. (2017) · Biomedical Engineering · doi:10.1007/s10527-017-9677-8 · Cited by 1
Caveats in diagnosis of osteoporosis
Acharya, S., Adsul, N. M., Palukuri, N., & Acharya, A. S. (2017) · Indian Journal of Medical Specialities · doi:10.1016/j.injms.2017.05.004 · Cited by 3
Perkins, J. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-54493-9_18 · Cited by 1
Chun, S. W. (2017) · Kosin Medical Journal · doi:10.7180/kmj.2017.32.1.5 · Cited by 1
Lv, Y., Li, Z. Y., He, K., Gao, Y., Xiao, X., Liu, Y., & Wang, G. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4871 · Cited by 1
Firoz, A., Murugharaj, S. S., Kandasamy, R., & Najimudeen, S. (2017) · International Journal of Research in Orthopaedics · doi:10.18203/issn.2455-4510.intjresorthop20173940 · Cited by 3
Brunelli, A. S., Baptista, C. M. S., Dominoni, R. L., et al. (2018) · Arquivos Catarinenses de Medicina · doi:10.63845/vfjjg196 · Cited by 1
Raiser, S. N., & Alfano, A. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-48323-0.00010-x · Cited by 2
COPD and Comorbidities: Relating Mechanisms and Treatment
Stratev, V., Dimitrova, V., & Petkova, D. (2018) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x14666181018101021 · Cited by 1
Vitamin D and Omega-3 Fatty Acid Trial 2017: Addressing Effects on Muscle and Bone
LeBoff, M. S., Donlon, C. M., Chou, S. H.-H., Cook, N. R., Buring, J. E., & Manson, J. E. (2018) · Springer eBooks · doi:10.1007/978-3-319-98464-3_2 · Cited by 1
Self-citationBenito, D. (2018) · Springer eBooks · doi:10.1007/978-3-319-96998-5_8 · Cited by 3
Hamoud, H. S., Ghait, M. M., Hussein, Y. A., & Harb, M. M. (2019) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2019.23682 · Cited by 1
Giray, E., & Akyüz, G. (2018) · Turkish Journal of Osteoporosis · doi:10.4274/tod.galenos.2018.07830 · Cited by 1
Correa‐Rodríguez, M., Mansouri-Yachou, J. E., Tapia-Haro, R. M., Molina, F., Rueda‐Medina, B., & Aguilar‐Ferrándiz, M. E. (2019) · Biological Research For Nursing · doi:10.1177/1099800419838625 · Cited by 1
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.